There are currently 71 active clinical trials seeking participants for Metastatic Cancer research studies. The states with the highest number of trials for Metastatic Cancer participants are California, Ohio, Michigan and Illinois.
Using a PET Imaging Agent, 18F-Clofarabine (CFA), to Measure Deoxycytidine Kinase Activity in Metastatic Cancer
NCT05065736
Recruiting
The purpose of this study is to evaluate whether a new type of imaging study, called 18F-Clofarabine (CFA) PET/CT, can be used to image cancer pyrimidine metabolism in participants. PET (positron emission tomography) imaging is a way of looking at cancers that can reveal cancer metabolism. Presently, however, there are no imaging agents in routine use to look at an aspect of cancer metabolism (pyrimidine metabolism) that dictates whether certain cancer drugs, e.g., gemcitabine, are likely to be... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/13/2024
Locations: Cleveland Clinic, Case Comprehensive Cancer Center, Cleveland, Ohio
Conditions: Metastatic Cancer, Carcinoma, Adenocarcinoma
Register for Updates
A Study of AZD1390 and Stereotactic Body Radiotherapy (SBRT) for People With Metastatic Solid Tumor Cancer
NCT05678010
Recruiting
The purpose of this study is to find out whether AZD1390 combined with stereotactic body radiation therapy/SBRT is a safe treatment for people with metastatic solid tumor cancer
Gender:
All
Ages:
18 years and above
Trial Updated:
06/21/2024
Locations: Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown, New Jersey +4 locations
Conditions: Solid Tumor, Metastatic Solid Tumor, Solid Carcinoma, Solid Tumor, Adult, Metastatic Tumor, Metastatic Cancer
Register for Updates
A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer
NCT05566574
Recruiting
The purpose of this study is to test the safety of the study drug, RP-3500 when given in combination with palliative external beam radiotherapy (EBRT) to people who have metastatic solid tumor cancer with a mutation of the ATM gene. The study researchers will do tests to find the highest dose of RP3500 that causes few or mild side effects.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/21/2024
Locations: Memorial Sloan Kettering Basking Ridge (Limited Protocol Activites), Basking Ridge, New Jersey +6 locations
Conditions: Solid Tumor, Metastatic Cancer
Register for Updates
Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
NCT05853575
Recruiting
This study will evaluate the efficacy of two dosing regimens of adagrasib (600 mg BID versus 400 mg BID) in patients with NSCLC with KRAS G12C mutation.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/17/2024
Locations: Providence Medical Foundation, Santa Rosa, California +20 locations
Conditions: Advanced Cancer, Metastatic Cancer, Malignant Neoplasm of Lung
Register for Updates
Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
NCT03785249
Recruiting
This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with advanced solid tumors that have a KRAS G12C mutation.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/17/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama +97 locations
Conditions: Advanced Cancer, Metastatic Cancer, Malignant Neoplastic Disease
Register for Updates
A Study of MGC026 in Participants With Advanced Solid Tumors
NCT06242470
Recruiting
The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of MGC026 in participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tumors The study has a dose escalation portion and a cohort expansion portion of the study. Participants will receive MGC026 by intravenous (IV) infusion. The dose of MGC026 will be assigned at the time of enrollment. Participants may receive up to 35 treatments... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/17/2024
Locations: START Midwest, Grand Rapids, Michigan +3 locations
Conditions: Advanced Solid Tumor, Advanced Cancer, Metastatic Cancer, Squamous Cell Carcinoma of Head and Neck, Non Small Cell Lung Cancer, Small-cell Lung Cancer, Bladder Cancer, Sarcoma, Endometrial Cancer, Melanoma, Castration Resistant Prostatic Cancer, Cervical Cancer, Colorectal Cancer, Gastric Cancer, Gastro-esophageal Cancer, Pancreas Cancer, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma, Platinum-resistant Ovarian Cancer
Register for Updates
A Study of DS-9606a in Patients With Advanced Solid Tumors
NCT05394675
Recruiting
This study will assess the safety and tolerability of DS-9606a in patients with advanced solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/14/2024
Locations: SCRI at HealthONE, Denver, Colorado +6 locations
Conditions: Advanced Cancer, Metastatic Cancer, Ovarian Cancer, Germ Cell Tumor
Register for Updates
FOG-001 in Locally Advanced or Metastatic Solid Tumors
NCT05919264
Recruiting
The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/07/2024
Locations: Honor Health, Scottsdale, Arizona +8 locations
Conditions: Cancer, Colorectal Cancer, Solid Tumor, Locally Advanced Solid Tumor, Metastatic Cancer, Gastric Cancer, Non-small Cell Lung Cancer, Non-small Cell Carcinoma, Non-small Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer Stage IIIB, Non-Small Cell Carcinoma of Lung, TNM Stage 4, Gastroesophageal-junction Cancer, WNT Pathway, β-catenin, Beta-catenin, Adenomatous Polyposis Coli, APC
Register for Updates
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
NCT04585750
Recruiting
This Phase 1/2 study will assess the safety, tolerability, and efficacy of multiple dose levels of PC14586 (INN: rezatapopt) alone (monotherapy) and in combination with pembrolizumab in participants with advanced solid tumors containing a TP53 Y220C mutation.
Gender:
All
Ages:
12 years and above
Trial Updated:
06/05/2024
Locations: USC Norris Comprehensive Cancer Center, Los Angeles, California +56 locations
Conditions: Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor, Lung Cancer, Ovarian Cancer, Endometrial Cancer, Prostate Cancer, Colorectal Cancer, Breast Cancer, Other Cancer, Locally Advanced, Head and Neck Cancer
Register for Updates
Triage of Advanced Cervical Cancer Through Immunotherapy Induction (TRACTION)
NCT05475171
Recruiting
To learn if MGD019 can help to control cervical cancer in patients who have yet to receive treatment.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/05/2024
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Metastatic Cancer, Cervical Cancer
Register for Updates
A Study of Reduced-dose Radiation in People With Metastatic Tumors With a Genetic Change
NCT05010031
Recruiting
This study will test whether reduced-dose radiotherapy is an effective treatment for metastatic tumors with an ATM mutation. The researchers want to find the lowest dose of radiation that would still be effective to treat these tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/05/2024
Locations: Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey +6 locations
Conditions: Metastatic Cancer
Register for Updates
A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815
NCT05557045
Recruiting
This phase 1 study will investigate the safety, dosing, and initial antitumor activity of JZP815 in participants with advanced or metastatic solid tumors harboring alterations in the MAPK pathway.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/31/2024
Locations: SCRI HealthOne, Denver, Colorado +7 locations
Conditions: Advanced Cancer, Metastatic Cancer, Solid Tumor
Register for Updates